Jump to content
 







Main menu
    


Navigation  


●Main page
 ●Contents
 ●Current events
 ●Random article
 ●About Wikipedia
 ●Contact us
 ●Donate
  



Contribute  


●Help
 ●Learn to edit
 ●Community portal
 ●Recent changes
 ●Upload file
  







Search  

































●Create account

●Log in
 









●Create account
 ● Log in
  



Pages for logged out editors learn more  


●Contributions
 ●Talk
  


















Contents

   



(Top)
  


1 References  













Deuremidevir






●Українська
  
Edit links
  








●Article
 ●Talk
  
















●Read
 ●Edit
 ●View history
  







Tools
    


Actions  


●Read
 ●Edit
 ●View history
  



General  


●What links here
 ●Related changes
 ●Upload file
 ●Special pages
 ●Permanent link
 ●Page information
 ●Cite this page
 ●Get shortened URL
 ●Download QR code
 ●Wikidata item
  



Print/export  


●Download as PDF
 ●Printable version
  















Appearance
    

 





From Wikipedia, the free encyclopedia
  

Deuremidevir
Clinical data
Trade names民得维
Other namesVV116, JT001, mindeudesivir, renmindevir
Routes of
administration		oral
Legal status
Legal status
  • US: Investigational drug
  • CN: conditially Rx
    • Identifiers

    • [(2R,3R,4R,5R)-5-(4-amino-5-deuteriopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-bis(2-methylpropanoyloxy)oxolan-2-yl]methyl 2-methylpropanoate

    CAS Number
    PubChem CID
    ChemSpider
    UNII
    Chemical and physical data
    FormulaC24H30DN5O7
    Molar mass502.546 g·mol−1
    3D model (JSmol)

    • [2H]c2cc([C@]1(C#N)O[C@H](COC(=O)C(C)C)[C@@H](OC(=O)C(C)C)[C@H]1OC(=O)C(C)C)n3ncnc(N)c23

    • InChI=InChI=1S/C24H31N5O7/c1-12(2)21(30)33-9-16-18(34-22(31)13(3)4)19(35-23(32)14(5)6)24(10-25,36-16)17-8-7-15-20(26)27-11-28-29(15)17/h7-8,11-14,16,18-19H,9H2,1-6H3,(H2,26,27,28)/t16-,18-,19-,24+/m1/s1/i7D

    • Key:RVSSLHFYCSUAHY-QXMJNOOVSA-N

    Deuremidevir, also known as VV116, is an nucleoside analogue antiviral drug. It is administrated through oral tablets, which contain the hydrobromide salt of this drug.[1]

    The drug is a deuterated tri-isobutyrateofGS-441524, the active metaboliteofremdesivir. It was first described in a November 2020 preprint by a team including members of Wuhan Institute of Virology and Vigonvita.[2] It completed a phase 3 trial in 2022.[3] Results from a separate Phase 3 trial conducted in mainland China from October 2022 to January 2023 suggested that deuremidevir may shorten the duration of COVID-19 symptoms in non-hospitalized adults with mild-to-moderate disease compared to placebo.[4] Junshi, which markets the drug, received conditional approval from China's National Medical Products Administration in January 2023.[5][6]

    In November 2023, in response to viral mutations and changing characteristics of infection, the WHO adjusted its treatment guidelines. Among other changes, the use of deuremidevir was recommended against, except for clinical trials.[7]

    References[edit]

    1. ^ Zhu KW (September 2023). "Deuremidevir and Simnotrelvir-Ritonavir for the Treatment of COVID-19". ACS Pharmacology & Translational Science. 6 (9): 1306–1309. doi:10.1021/acsptsci.3c00134. PMC 10496140. PMID 37705591.
  • ^ Yin W, Luan X, Li Z, Xie Y, Zhou Z, Liu J, Gao M, Wang X, Zhou F, Wang Q, Wang Q (November 2020). "Structural basis for repurpose and design of nucleoside drugs for treating COVID-19". bioRxiv. doi:10.1101/2020.11.01.363812. S2CID 226263471.
  • ^ Cao Z, Gao W, Bao H, Feng H, Mei S, Chen P, et al. (February 2023). "VV116 versus Nirmatrelvir-Ritonavir for Oral Treatment of Covid-19". The New England Journal of Medicine. 388 (5): 406–417. doi:10.1056/NEJMoa2208822. PMC 9812289. PMID 36577095.
  • ^ Fan X, Dai X, Ling Y, Wu L, Tang L, Peng C, Huang C, Liu H, Lu H, Shen X, Zhang W, Wang F, Li G, Li M, Huang Y, Zhang H, Li M, Ren F, Li Y, Liu C, Zhou Z, Sun W, Yi Y, Zhou D, Gao H, Pan Q, Liu H, Zhao J, Ding Z, Ma Y, Li W, Wang Q, Wang X, Bai Y, Jiang X, Ma J, Xie B, Zhang K, Li L (February 2024). "Oral VV116 versus placebo in patients with mild-to-moderate COVID-19 in China: a multicentre, double-blind, phase 3, randomised controlled study". The Lancet Infectious Diseases. 24 (2): 129–139. doi:10.1016/S1473-3099(23)00577-7. PMID 38006892.
  • ^ Devarasetti H (2023-01-30). "China's NMPA conditionally approves two oral drugs for Covid-19". Pharmaceutical Technology. Retrieved 2023-02-04.
  • ^ Liu W, Zhang M, Hu C, Song H, Mei Y, Liu Y, Zhang Q (November 2023). "Remdesivir Derivative VV116 Is a Potential Broad-Spectrum Inhibitor of Both Human and Animal Coronaviruses". Viruses. 15 (12): 2295. doi:10.3390/v15122295. PMC 10748125. PMID 38140536.
  • ^ "WHO updates its guidance on treatments for COVID-19". BMJ (Press release). 9 November 2023.

    • Retrieved from "https://en.wikipedia.org/w/index.php?title=Deuremidevir&oldid=1226034348"
    Categories: 
    ●Anti–RNA virus drugs
     ●Antiviral drugs
     ●Deuterated compounds
     ●Isobutyrate esters
     ●Nitriles
     ●Nucleosides
     ●COVID-19 drug development
     Hidden categories: 
    ●Articles with short description
     ●Short description is different from Wikidata
     ●Drugs with non-standard legal status
     ●Articles without EBI source
     ●Chemical pages without DrugBank identifier
     ●Articles without KEGG source
     ●Drugs missing an ATC code
     ●Articles containing unverified chemical infoboxes
      


    ●This page was last edited on 28 May 2024, at 05:35 (UTC).
    ●Text is available under the Creative Commons Attribution-ShareAlike License 4.0; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization.


    ●Privacy policy
    ●About Wikipedia
    ●Disclaimers
    ●Contact Wikipedia
    ●Code of Conduct
    ●Developers
    ●Statistics
    ●Cookie statement
    ●Mobile view


    Wikimedia Foundation
    Powered by MediaWiki